Diabetes
-
Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.
Load moreType 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the overall mortality significantly increased by strict control of blood glucose (target HbA1c <6%) compared with a less stringent control (target HbA1c of approximately 7%). Strict glucose control resulted in a significantly higher likelihood of developing severe hypoglycaemia, while severe hypoglycaemia was itself associated with death due to CVD.
Load Less
Webinars
-
Prof Holger Nef, Dr Kambis Mashayekhi, Dr Miroslaw Ferenc
Type 2 Diabetes Mellitus
CV Outcomes in Diabetes
Risk reduction with antihyperglycemics
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).
The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.
CV specialists are well-positioned to play a key role in managing patients with T2D including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycemic agents into routine practice.
The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.
Section Editor
Saint Luke's America Heart Institute, Kansas City, MO, US
Clinical publications
-
Fan W, Tong C, Wong ND. Cardiovasc Drugs Ther 2020; epub ahead of press.
-
Janus C, Lundgren JR, Jensen S, et al. Diabetes 2020;69(Suppl1):139-OR.
-
Vaduganathan M, Fonarow GC, Greene SJ, et al. JACC Heart Fail 2020;8:469–80.
-
Carbone S, Billingsley HE, Canada JM, et al. Diabetes Metab Res Rev 2020; epub ahead of press.
-
Davis WA, Hellbusch V, Hunter ML, et al. J Clin Med 2020;9:e1428.
-
Griffin M, Rao VS, Ivey-Miranda J, et al. Circulation 2020; epub ahead of press.
Pages
Ongoing trials
Pages
Review articles
-
Li J, Albajrami O, Zhuo M, et al. Clin J Am Soc Nephrol 2020;15:1678–88.
-
Davies MJ, Kloecker DE, Webb DR, et al. Diabetes Obes Metab 2020; epub ahead of press.
-
Ghosh-Swaby OR, Goodman SG, Leiter LA, et al. Lancet Diabetes Endocrinol 2020;8:418–35.
-
Giorgino F, Vora J, Fenici P, Solini A. Diabetes Obes Metab 2020; epub ahead of press.
-
Heuvelman VD, Van Raalte DH, Smits MM. Cardiovasc Res 2020;116:916–30.
-
Clemens KK, Woodward M, Neal B, Zinman B. Diabetes Care 2020;43:1157–63.
Pages
Guidelines
Pages
Congress Updates
-
Mahapatra H, Khuntia M, Mahapatra L, et al. Diabetes 2019;68(Suppl 1):2349-PUB.
-
Liu J, Tarasenko L, Ellison ME, et al. Diabetes 2019;68(Suppl 1):2353-PUB.
-
Verma S, Böhm M, Brueckmann M, et al. Can J Cardiol 2019;35:S197.
-
Steven S, Helmstaedter J, Filippou K, et al. Eur Heart J 2019;40(Suppl 1):P4476.
-
Desouza C, Bain SC, Gondolf T, et al. Eur Heart J 2019;40(Suppl 1):P6271.
-
Ikonomidis I, Birba D, Thymis J, et al. Eur Heart J 2019;40(Suppl 1):P4991.
Pages
Pages
